Best virtual data rooms for biotech

A biotech’s balance sheet is mostly intangible; the value sits in a few hundred documents a patent will never fully cover. Every raise hands more of that value to more outsiders. This page ranks rooms around the financing arc, not a single deal, and shows how to wall one off before a new investor logs in.

The room is picked by your cap table

Most VDR rankings are tuned for a one-off deal desk: staged bidders, Q&A speed, engagement dashboards. A venture-backed biotech runs a different pattern. You open and reopen a room across years of raises, and each round changes both the audience and the slice of science on show.

• The syndicate widens every round. A seed lead becomes a Series B crowd becomes a crossover book. More eyes on more unpatented material, some of whom back a rival next quarter.
• The data slice deepens. A thesis at seed becomes an IND-enabling package at Series B becomes the full dossier before a public exit. The room has to grow its controls in step.
• A leak is permanent. You can reprice a term sheet. You cannot un-share a process route a competitor has now seen, so the controls have to outlast the deal.
• The team stays tiny. Founders run the round between experiments, so the room must be fast to stand up and cheap enough for a pre-revenue company to justify.

What each raise puts in the room

Map the round to the audience and the slice, and the evaluation stays honest. You are not buying the same room at seed and at crossover.

Each raise widens the syndicate and deepens the data slice.

The crossover round, marked in coral, is the biotech stress point: the widest syndicate meets the fullest dossier just before public markets or a sale, often with funds that also back competing programs. Weight your choice for that moment, not the friendly seed.

Raise	Who is in the room	Data slice exposed	Room priority
Seed / pre-seed	A few angels, a lead micro-VC	Thesis, founding IP, MTA terms	Fast, cheap, watermark the science
Series A	Lead VC plus a small syndicate	Preclinical package, cap table, tech-transfer licence	View-only research folders, group walls
Series B	Larger syndicate, new leads	IND-enabling data, CMC outline	Persistent DRM on CMC, per-group access
Crossover / pre-IPO	Crossover funds, bankers	Full dossier, financials, regulatory	Audit trail, remote revoke, SSO
Reverse merger / trade sale	Acquirer or shell, their counsel	Everything, under formal diligence	Complete audit trail, verifiable certs

From academic spinout to out-license

A large share of biotechs begin in a university lab, and that origin shapes the room before any investor arrives. Your first job is to prove clean provenance, then to disclose it without breaching the agreements you signed to get here.

• Tech-transfer licence and invention assignments. Investors read these first, because a shaky chain of title sinks a program faster than a failed assay. Keep them in a restricted corporate folder, not the open research set.
• Material transfer agreements (MTAs). Cell lines, reagents and constructs brought from the academic lab often carry field-of-use or confidentiality limits. An MTA can restrict what you are even allowed to show a commercial partner, so check it before a folder goes live.
• Publication and thesis history. What is already public narrows what still counts as a trade secret. Track it, so you do not spend DRM effort guarding material a journal printed two years ago.

The practical move: wall the spinout paperwork off from the science, and let the MTA terms, not convenience, decide which materials data a given reviewer can open.

Platform or single asset

The disclosure problem splits along the shape of the company, and it changes your DRM strategy more than any single feature does.

• Platform biotech. The value is a reusable technology that spins out many programs. Guard the platform’s core methods hardest, and meter per-program data so a partner licensing one asset never sees the engine behind the rest.
• Single-asset biotech. Everything rides on one molecule, so one dossier carries the whole company. There is nothing to hold back for later, which means view-only and persistent DRM on that package matter more than segmentation across programs.

Security and IP control across the shortlist

The table scores the six rooms biotech teams shortlist most on the controls that protect research and travel with a downloaded file, not on deal-desk throughput. Figures reflect our own benchmark; scope varies by plan, so confirm on a real sample before you rely on it.

These six are the biotech top six our benchmark ranks, so they line up with the shortlist and criteria table further down this page. Note where Ellty differs: it is the one on published pricing and the only one without SSO on entry plans, and its DRM is in-room rather than post-download.

Matching the six to your raise

• Highest-IP out-licensing and partnering. ShareVault is the familiar name in these rooms, built on persistent document-level DRM and page-level analytics with deep life-sciences pedigree; it is quote-only and heavier to stand up.
• Control after a file leaves. BlackBerry Workspaces and Intralinks hold governance on a downloaded file through remote revoke and information-rights management, and BlackBerry adds an on-premise option for the strictest programs.
• A fast, self-serve seed or Series A room. Ellty suits founders who want a room live within the hour, with per-user permissions, dynamic watermarking and a full audit trail from $149 a month. Pair it with tight download rules on the preclinical folders, since its DRM is in-room.
• Cross-border syndicate diligence. iDeals brings redaction, SSO and ISO 27001 for tangled multi-jurisdiction rounds.
• A crossover round or trade sale at scale. Datasite carries buyer-engagement analytics and AI redaction built for large, high-volume diligence, the shape of a pre-IPO or acquisition process.

When two look close, set them side by side. Our Ellty vs iDeals comparison and the full comparison table settle it fastest.

Budget a room for a multi-year raise

A pre-revenue biotech feels every recurring cost, so it helps to see the shape of the bill before a sales call. The estimator turns page count, storage, reviewer count and process length into an indicative monthly and total range.

Two numbers move a biotech bill most: round length and page count. A raise that drags from a planned 90 days to eight months roughly doubles a monthly-billed room, and a document-heavy CMC load can spike a per-page plan fast.

For most biotech work a flat-rate room caps that risk. Our guide to per-page versus flat-rate pricing walks the maths, and the pricing overview lines up indicative rates in one place.

Where the room stops

A data room is a disclosure surface, not a regulated records system, and biotech is where teams most often blur the two.

• The room holds a curated slice. Assemble the IND-enabling and CMC package you want a partner or investor to review, and govern it with DRM, permissions and an audit trail.
• The validated systems stay put. GxP quality records, eCTD submissions and 21 CFR Part 11 electronic records live in the systems built and validated for them. A diligence room supports the conversation around them; it does not replace them.
• HIPAA is conditional. If a program touches identifiable patient data, confirm the provider will sign a business associate agreement rather than trusting a badge.

Keep regulated records in their home systems and open a room to disclose, not to store.

Lock down the room before anyone logs in

The order you build in decides whether a room is safe on day one or leaky until you notice. Structure first, wall off by audience second, then turn on the controls before a single external invite exists.

How to lock down a biotech data room

A short setup a founder can run before opening a room to a new investor syndicate or a partner.

Estimated time: 45min

1. 1

   Separate provenance, corporate and science

   Build folders that isolate the spinout paperwork, tech-transfer licence and MTAs from the preclinical, assay and CMC material, because those sets almost never share an audience.

2. 2

   Create permission groups before people

   Set up isolated groups for each raise's syndicate, a CRO and an acquirer, and grant folder rights to the group, so adding a reviewer later is one invite rather than a rebuild.

3. 3

   Turn on watermarking and view-only

   Enable dynamic watermarking and view-only rendering on the research and IP folders, and switch off download entirely on the most sensitive slice.

4. 4

   Require 2FA or SSO on every external account

   Enforce two-factor or single sign-on before any invite, so a shared password is never enough to reach a molecule dossier. Some rooms lean on SSO in place of 2FA, so confirm which your plan enforces.

5. 5

   Test control as an outside reviewer

   Log in as a test external user, confirm you see only the intended slice, then, where the room supports it, download a file and verify revoke actually cuts the copy off.

Step five is the one founders skip and later regret. A control that works in a calm setup is the only control you can count on when a round stalls and your data is already on a stranger’s laptop.

Honest trade-offs

A DRM-heavy room is not free of friction, and a biotech should weigh both sides before committing a multi-year raise to one.

The line most teams settle on: use in-room controls freely for a signed partner, and reserve the heaviest post-download DRM for a first diligence with a party you have reason to guard against.

Frequently asked questions

Does the right biotech data room change as we raise more?

Often, yes. A seed round exposes a thesis to a couple of backers, where a fast, cheap, self-serve room is enough. A crossover or pre-IPO round opens the full dossier to a wide syndicate that may include competitors' investors, which is where persistent DRM, remote revoke, SSO and a verifiable audit trail start to earn their cost. Many teams start light and step up as the syndicate widens, rather than overbuying at seed.

How do we handle IP that came from a university spinout?

Provenance is the first thing investors check, so keep the tech-transfer licence, invention assignments and any material transfer agreements in a restricted corporate folder, separate from the open science. MTAs matter most: a material brought from the academic lab can carry field-of-use or confidentiality limits that restrict what you may disclose to a commercial partner, so read them before a folder goes live rather than after an investor asks.

Platform company or single asset, does the room choice differ?

It changes your DRM strategy. A platform biotech should guard the reusable core methods hardest and meter per-program data, so a partner licensing one asset never sees the engine behind the rest. A single-asset company has one dossier carrying the whole business, so view-only rendering and persistent DRM on that package matter more than segmentation across programs. Match the controls to which of the two you are.

How much should a pre-revenue biotech expect to pay?

Some rooms publish rates from around $120 to $150 a month, which suits an early raise, while the most IP-focused rooms are quote-only and price on process length and reviewer count. Budget against how long the round runs and how large the syndicate grows, not a headline monthly figure, and watch per-page billing, which can spike on a document-heavy CMC load. Confirm current pricing with the provider.

Is a data room enough for our IND-enabling and CMC package?

For disclosure, yes; for the record of truth, no. A room can assemble and govern a curated IND-enabling or CMC slice for a partner or investor to review, with DRM, permissions and an audit trail. But your validated GxP quality records, eCTD submissions and 21 CFR Part 11 electronic records belong in the systems built and validated for them. Use the room to disclose a slice, not to replace those systems.

The lesson holds from the first seed cheque to a trade sale: for biotech the best data room is the one that keeps controlling a document long after it has left your lab, and grows its controls as each raise widens the room. For the science-and-compliance backdrop, see our guide to data rooms for life sciences; for the money side, the shortlists for fundraising and for an IPO.